Myelodysplastic Syndrome (MDS)

Protocol Number	Study Title

CTSU E2905	Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa(Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia

SWOG E1905	A Randomized Phase II Trial of Azacitidine with or without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage Dysplasia ECOG Study